Ideaya Biosciences (IDYA) announced that Daniel Simon will join the company as its chief business officer in August. Simon most recently served as chief business officer at Revolution Medicines (RVMD) from 2022 to 2024.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences price target lowered to $55 from $57 at JPMorgan
- Ideaya Biosciences reports Q1 EPS (53c), consensus (51c)
- IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
- Ideaya Biosciences announces selection of move-forward expansion dose for IDE397
- Ideaya Biosciences announces inducement grants under Nasdaq listing rule